Patents by Inventor Eric J. Gilbert

Eric J. Gilbert has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SUBSTITUTED PIPERAZINES AS CB1 ANTAGONISTS
    Publication number: 20100286160
    Abstract: Compounds of Formula (I): or pharmaceutically acceptable salts, solvates, or esters thereof, are useful in treating diseases or conditions mediated by CB1 receptors, such as metabolic syndrome and obesity, neuroinflammatory disorders, cognitive disorders and psychosis, addiction (e.g., smoking cessation), gastrointestinal disorders, and cardiovascular conditions.
    Type: Application
    Filed: June 25, 2008
    Publication date: November 11, 2010
    Inventors: Eric J. Gilbert, William J. Greenlee, Sarah Wei Li, Michael W. Miller, Jack D. Scott, Adrew Stamford, Chander Shekher Celly
  • SUBSTITUTED PIPERAZINES AS CB1 ANTAGONISTS
    Publication number: 20100249144
    Abstract: Compounds of Formula (I) or pharmaceutically acceptable salts, solvates, or esters thereof, are useful in treating diseases or conditions mediated by CB1 receptors, such as metabolic syndrome and obesity, neuroinflammatory disorders, cognitive disorders and psychosis, addiction (e.g., smoking cessation), gastrointestinal disorders, and cardiovascular conditions.
    Type: Application
    Filed: June 25, 2008
    Publication date: September 30, 2010
    Inventors: Duane Eugene Demong, Michael W. Miller, Eric J. Gilbert, Jack D. Scott, Andrew Stamford, William J. Greenlee, Chander Shekher Celly
  • Bipiperdine derivatives useful as CCR3 antagonists
    Patent number: 7705153
    Abstract: The use of CCR3 antagonists of the formula I or a pharmaceutically acceptable salt thereof for the treatment of asthma is disclosed, as well as novel compounds of the formula II, pharmaceutical compositions comprising them, and their use in the treatment of asthma, wherein R, Ra, X, Xa, R1, R2, R2a, R14, R14a, R16 and n are as defined in the specification.
    Type: Grant
    Filed: February 2, 2005
    Date of Patent: April 27, 2010
    Assignee: Schering Corporation
    Inventors: Pauline C. Ting, Jianhua Cao, Youhao Dong, Eric J. Gilbert, Ying Huang, Joseph M. Kelly, Stuart McCombie, Neng-Yang Shih
  • Substituted piperazines as CB1 antagonists
    Patent number: 7700597
    Abstract: Compounds of Formula (I): or pharmaceutically acceptable salts, solvates, or esters thereof, are useful in treating diseases or conditions mediated by CB1 receptors, such as metabolic syndrome and obesity, neuroinflammatory disorders, cognitive disorders and psychosis, addiction (e.g., smoking cessation), gastrointestinal disorders, and cardiovascular conditions.
    Type: Grant
    Filed: December 1, 2005
    Date of Patent: April 20, 2010
    Assignee: Schering Corporation
    Inventors: Eric J. Gilbert, Michael W. Miller, Jack D. Scott, Andrew W. Stamford, William J. Greenlee, Jay Weinstein
  • Substituted Piperazines as CB1 Antagonists
    Publication number: 20100029607
    Abstract: Compounds of Formula (I): or pharmaceutically acceptable salts, solvates, or esters thereof, are useful in treating diseases or conditions mediated by CB1 receptors, such as metabolic syndrome and obesity, neuroinflammatory disorders, cognitive disorders and psychosis, addiction (e.g., smoking cessation), gastrointestinal disorders, and cardiovascular conditions.
    Type: Application
    Filed: September 22, 2009
    Publication date: February 4, 2010
    Inventors: Eric J. Gilbert, Michael W. Miller, Jack D. Scott, Andrew W. Stamford, William J. Greenlee, Jay Weinstein
  • Substituted Piperazines as CB1 Antagonists
    Publication number: 20090105208
    Abstract: Compounds of Formula (I): or pharmaceutically acceptable salts, solvates, or esters thereof, are useful in treating diseases or conditions mediated by CB1 receptors, such as metabolic syndrome and obesity, neuroinflammatory disorders, cognitive disorders and psychosis, addiction (e.g., smoking cessation), gastrointestinal disorders, and cardiovascular conditions.
    Type: Application
    Filed: June 25, 2008
    Publication date: April 23, 2009
    Inventors: Eric J. Gilbert, Michael W. Miller, Jack D. Scott, Duane Eugene DeMong, Andrew Stamford, William J. Greenlee, Chander Shekher Celly